Fungal infections in pediatric intensive care units

Area of Science:

• Pediatric Infectious Diseases
• Mycology
• Clinical Pharmacology

Background:

• Pediatric fungal infections present significant morbidity and mortality risks.
• Limited large-scale antifungal clinical trials exist for neonates and children.
• Clinicians often extrapolate adult trial data for pediatric candidemia management.

Purpose of the Study:

• To address the lack of pediatric-specific antifungal trial data.
• To inform evidence-based treatment strategies for pediatric fungal infections.
• To evaluate current guideline recommendations in pediatric populations.

Main Methods:

• Review of existing pediatric antifungal trial data.
• Analysis of guideline recommendations for pediatric candidemia.
• Identification of research gaps in pediatric antifungal therapy.

Main Results:

• Few adequately powered antifungal trials have been conducted in pediatric populations.
• Adult trial data is frequently used to guide pediatric treatment decisions.
• Current guidelines suggest fluconazole or echinocandins, with a preference for echinocandins in specific high-risk pediatric cases.

Conclusions:

• There is a critical need for more robust antifungal clinical trials in neonates and children.
• Current management of pediatric candidemia relies heavily on adult data, necessitating further pediatric research.
• Guidelines provide a framework but require validation and refinement through pediatric-specific studies.